For the first time in Medicare history, beneficiaries will be able to use their Medicare benefits to cover GLP-1 weight loss medications. Starting July 1, 2026, Medicare will launch the GLP-1 Bridge program, a temporary program that covers three GLP-1 medications with a flat $50 monthly copay. This is a significant shift, as Medicare Part D has never before covered any weight loss medications.
If you're a Medicare beneficiary considering a GLP-1 medication, here's what you need to know about coverage, eligibility, cost, and what happens when this program ends.
The GLP-1 Bridge program is a temporary Medicare initiative running from July 1, 2026 through December 31, 2026. It's designed to provide an affordable access point for weight loss GLP-1 medications while Medicare transitions to the BALANCE Model, a longer-term coverage program launching in 2027.
The program operates outside the standard Part D benefit structure, which means Part D sponsors (your insurance plan) are not involved in administering it. This is important because it also means the $50 copay does not count toward your Part D deductible or your $2,100 out-of-pocket spending cap.
The GLP-1 Bridge program covers three GLP-1 weight loss medications, but with specific formulation restrictions:
| Medication | Covered Formulations | NOT Covered |
|---|---|---|
| Foundayo (semaglutide) | All formulations | None |
| Wegovy (semaglutide) | All formulations | None |
| Zepbound (tirzepatide) | KwikPen only | Single-dose vial, single-dose pen |
This means if you use Zepbound, the program covers the multi-dose KwikPen pen but not the single-dose vial or single-dose pen. Foundayo and Wegovy are covered in all available formulations, including the newly available oral (pill) versions.
The GLP-1 Bridge program offers a simple cost structure: $50 per month, regardless of which eligible medication you're using or what dose you're on.
Important details about this $50 copay:
To put this in context: without insurance, Wegovy and Zepbound cost roughly $1,000 to $1,350 per month. Even with manufacturer discount programs for uninsured patients, you're typically paying $150 to $450 per month. The $50 Medicare copay represents the most affordable option available to Medicare beneficiaries.
The GLP-1 Bridge program is available to all Medicare Part D beneficiaries (the vast majority of Medicare beneficiaries). Eligibility requirements and enrollment details will be clarified by CMS in the coming months as we approach July 2026.
To check your eligibility and enroll:
Enrollment details may vary by plan, so it's worth contacting your current Part D insurance provider a few months before July to ask about their specific enrollment process.
It's important to understand what's new here. Medicare Part D has already covered GLP-1 medications for years, but only when prescribed for type 2 diabetes (Ozempic, Mounjaro, Trulicity, etc.). Those medications work by controlling blood sugar, and diabetes is an approved indication.
What's new is coverage specifically for weight loss. Wegovy, Zepbound, and Foundayo are approved by the FDA solely for chronic weight management in people without diabetes. This is the first time Medicare has covered any medication primarily for weight loss, which is a meaningful policy shift.
If you use a GLP-1 for diabetes, your Part D plan continues to cover it as before. If you use one for weight loss, the new GLP-1 Bridge program applies starting July 2026.
The GLP-1 Bridge is temporary. It runs through December 31, 2026 only. After that, Medicare transitions to the BALANCE Model, a longer-term coverage framework that also includes Medicaid.
The BALANCE Model is expected to launch in Medicaid as early as May 2026 and in Medicare Part D in January 2027. The details of copays, formulary status, and eligible medications under BALANCE have not yet been finalized by CMS, so we'll know more as 2026 progresses.
The key takeaway: if you start a GLP-1 medication during the Bridge program and want to continue after December 2026, you'll want to stay informed about BALANCE Model details well before the transition happens.
If you're a Medicare beneficiary interested in a GLP-1 medication for weight loss:
Now (before July 2026): Schedule a conversation with your primary care doctor or a weight loss specialist. Discuss whether a GLP-1 medication is appropriate for you, which medication might be the best fit, and what to expect from treatment.
June 2026: Check your Part D plan's enrollment information for the GLP-1 Bridge program. You may be able to pre-enroll or learn about the process before July 1.
July 1 and after: Once the program launches, you can start the enrollment process and work with your pharmacy and doctor to get your prescription filled.
Use our free calculator to estimate timing, track your progress, and compare costs across different scenarios.
Open the GLP-1 Calculator